76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Cytek Biosciences Inc
Closed
SectorHealthcare
3.43 3.31
Overview
Share price change
24h
Min
3.28
Max
3.46
Income | -21M -11M |
|---|---|
Sales | -16M 41M |
EPS | -0.027 |
Profit margin | -27.503 |
Employees | 663 |
EBITDA | -13M -15M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +69.12% upside |
Next Earnings | 5 Aug 2025 |
|---|
Market Cap | -134M 358M |
|---|---|
Previous open | 0.12 |
Previous close | 3.43 |
News Sentiment
By Acuity
50%
50%
167 / 380 Healthcare
Technical Score
By Trading Central
Confidence
Weak Bullish Evidence
Cytek Biosciences Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Cytek Biosciences Inc Forecast
Price Target
By TipRanks
69.12% upside
12 Months Forecast
Average 5.75 USD 69.12%
High 8 USD
Low 4 USD
Based on 4 Wall Street analysts offering 12 month price targets forCytek Biosciences Inc - Dist in the last 3 months.
Sentiment
By Acuity
167 / 380 Healthcare
News Sentiment
Neutral
Volatility
Below average
News Volume (RCV)
Average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Cytek Biosciences Inc
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
